131 Additionally, somatostatin is also produced by endocrine cells in the central nervous system (resulting in decreased growth hormone secretion) and the GIT (resulting in slowed digestion)
Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia
While some experts and researchers have concerns about the drugs long-term impact and safety, many argue the benefits outweigh the known risks.
Myth: More ingredients = better results. Fact: More ingredients can also mean more variables (tolerability, interactions, unclear dosing)
Medications like orforglipron (an oral, non-peptide GLP-1 agonist), survodutide (a dual glucagon/GLP-1 agonist), and CagriSema (combining cagrilintide with semaglutide) are advancing through clinical trials
The benefits of GLP1 receptors in cardiovascular diseases Yifan Ren, et al